Daxor Corporation Reports 2025 Fiscal Year Results: Operating Revenue Up 45%, Net Asset Value Rises to $9.07 Per Share

Rhea-AI Summary

Daxor (Nasdaq: DXR) reported fiscal 2025 results with operating revenue up 45% YoY and total net assets of $45,887,266 as of December 31, 2025. Net Asset Value per share rose to $9.07 (a $1.82 increase). The company received FDA 510(k) clearance in August 2025 for a next‑generation portable Blood Volume Analyzer and closed a $9.0 million registered direct offering in January 2026 at $11.75 per share to fund commercialization and expansion.

Positive

• Operating revenue increased by 45% YoY
• Total net assets reached $45,887,266
• Net Asset Value per share rose to $9.07 (+$1.82)
• FDA 510(k) clearance received in August 2025
• Operating loss narrowed to $268,598 from $1,614,545
• Raised $9.0M registered direct offering in January 2026

Negative

• Operating division remains an operating loss of $268,598
• Company sold remaining investments in December 2025, concentrating resources
• Commercial rollout depends on recently raised capital for production
• Registered direct offering of $9.0M may dilute existing shareholders

Key Figures

Total net assets: $45,887,266 NAV per share: $9.07 NAV per-share gain: $1.82 +5 more

8 metrics

Total net assets $45,887,266 As of December 31, 2025

NAV per share $9.07 As of December 31, 2025

NAV per-share gain $1.82 Increase vs. December 31, 2024

Net realized gains $745,334 Investment activity fiscal year 2025

Operating revenue growth 45% Unaudited operating revenues year-over-year

Operating loss 2025 $268,598 Operating division loss fiscal year 2025

Operating loss 2024 $1,614,545 Operating division loss fiscal year 2024

Registered direct offering $9 million at $11.75 Closed January 2026, post year-end

Market Reality Check

Price: $11.28 Vol: Volume 101,162 is 9.42x t...

high vol

$11.28 Last Close

Volume Volume 101,162 is 9.42x the 20-day average of 10,739, indicating elevated trading interest ahead of/around this report. high

Technical Shares at $11.38 are trading slightly above the 200-day MA of $11.32, while sitting 22.89% below the 52-week high and 67.35% above the 52-week low.

Peers on Argus

DXR fell 4.05% on heavy volume while sector peers were mixed: some down (e.g., A...

1 Down

DXR fell 4.05% on heavy volume while sector peers were mixed: some down (e.g., AKYA -8.51%, ZJYL -3.4%, MLSS -3.03%) and others up (ZTEK +4.54%, PDEX +3.64%). Only one peer (MBOT -6.45%) appeared in the momentum scanner, reinforcing this as a stock-specific move rather than a broad sector rotation.

Historical Context

5 past events · Latest: Feb 24 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 24	Outpatient program launch	Positive	-1.7%	Launched BVA diagnostic program in Southern Middle Tennessee expanding outpatient presence.
Feb 10	Reporting transition plan	Positive	-0.4%	Announced intent to move to Securities Exchange Act reporting aligned with operating focus.
Jan 23	Capital raise offering	Negative	-8.1%	Entered registered direct offering for 765,958 shares at $11.75 raising about $9M.
Nov 25	New facility adoptions	Positive	-1.9%	Expanded BVA platform into three new facilities with on-site and lab services.
Oct 21	Investor summit meetings	Positive	+2.0%	CEO scheduled institutional investor meetings at Maxim Growth Summit in New York.

Pattern Detected

Recent history shows multiple instances where seemingly positive operating or expansion news coincided with modest share price declines, while the capital-raising event saw a larger, aligned selloff.

Recent Company History

Over the past several months, DXR has focused on expanding its Blood Volume Analysis footprint and reshaping its corporate profile. On Oct 21, 2025, investor outreach at a growth summit coincided with a modest gain. Subsequent operating updates—including new facility adoptions on Nov 25, 2025, a reporting-framework shift on Feb 10, 2026, and an outpatient BVA program launch on Feb 24, 2026—were followed by small price declines. The Jan 23, 2026 $9M offering saw the sharpest drop, framing today’s strong 2025 results within a backdrop of dilution-sensitive trading.

Market Pulse Summary

This announcement underscores a pivotal year for DXR, with net assets reaching $45,887,266, NAV risi...

Analysis

This announcement underscores a pivotal year for DXR, with net assets reaching $45,887,266, NAV rising to $9.07 per share, and unaudited operating revenues up 45%. The operating loss narrowed to $268,598 even as the company invested in R&D and commercialization of its next‑generation analyzer. Subsequent completion of a $9 million registered direct offering and plans to adopt Securities Exchange Act reporting highlight a shift toward an operating-company profile. Investors may focus on revenue trajectory, operating leverage, and regulatory execution in coming periods.

Key Terms

fda 510(k) clearance, registered direct offering, net asset value, investment company act, +2 more

6 terms

fda 510(k) clearance regulatory

"The most significant corporate highlight of the year was the receipt of FDA 510(k) clearance in August 2025..."

FDA 510(k) clearance is an official approval from the U.S. Food and Drug Administration that allows medical devices to be legally sold in the United States. It indicates the device is considered safe and effective based on its similarity to already approved products. For investors, achieving 510(k) clearance can signal a company's readiness to bring a medical device to market and generate revenue.

registered direct offering financial

"Daxor successfully closed a $9 million registered direct offering in January 2026 at $11.75 per share."

A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.

net asset value financial

"Net Asset Value per share increased to $9.07, representing a $1.82 per share gain..."

Net asset value is the total value of an investment fund's assets minus any liabilities, divided by the number of shares or units outstanding. It represents the per-share worth of the fund, similar to how the value of a house is determined by its total worth after debts are subtracted. Investors use it to gauge the true value of their holdings and to compare different investment options.

investment company act regulatory

"transition its regulatory reporting framework to the Securities Exchange Act of 1934."

The Investment Company Act is a law that sets rules for businesses whose main activity is managing and selling pooled money, such as mutual funds and other investment funds. It matters to investors because it requires clear reporting, limits managers from putting their own interests ahead of clients, and mandates safekeeping and oversight of assets—similar to safety inspections and traffic rules that help keep shared vehicles reliable and trustworthy.

gaap financial

"provide investors with standardized GAAP metrics comparable to other high-growth medical diagnostic firms."

GAAP, or Generally Accepted Accounting Principles, are a set of standardized rules and guidelines that companies follow when preparing their financial statements. They ensure consistency, transparency, and comparability across different companies, making it easier for investors to understand and compare financial information accurately. This helps investors make informed decisions based on trustworthy and uniform financial reports.

closed-end investment company regulatory

"is registered as a closed‑end investment company but intends to seek an order..."

A closed-end investment company is a pooled investment fund that issues a fixed number of shares in a one-time offering and then has those shares bought and sold on an exchange like a stock; a professional manager runs the portfolio of assets. It matters to investors because the market price can move above or below the value of the underlying holdings, affecting returns and income, and shares may be less flexible to issue or redeem compared with open-ended funds—think of buying a slice of a privately baked pie whose market price can differ from the pie’s actual ingredients value.

AI-generated analysis. Not financial advice.

Strategic Realignment to Clinical Growth Supported by FDA 510(k) Clearance for Next-Generation Blood Volume Analyzer

Oak Ridge, TN, March 03, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces financial and operating results for the fiscal year ended December 31, 2025. The company reported a transformative year characterized by significant growth in its operating division and a substantial increase in total net assets.

FDA Milestone & Commercial Momentum

The most significant corporate highlight of the year was the receipt of FDA 510(k) clearance in August 2025 for Daxor’s next-generation rapid, compact, and portable Blood Volume Analyzer. Developed under contract with the U.S. Department of Defense. This new system delivers laboratory-grade diagnostic precision three times faster than previous models. The company is currently utilizing newly raised capital to assemble these next-generation units for placement while expanding its commercial sales team to meet enthusiastic market response.

Financial Performance Highlights

• Net Asset Value (NAV) Growth: Total net assets reached $45,887,266 as of December 31, 2025, an increase of over $10 million from the prior year.
• Per-Share Value: Net Asset Value per share increased to $9.07, representing a $1.82 per share gain compared to December 31, 2024.
• Investment Activity: The company recorded net realized gains on investment activity of $745,334 for the fiscal year. In December 2025, Daxor sold its remaining investment positions to focus 100% of resources on its primary blood volume business.
  
  

Operating Division Momentum

Daxor’s operating division saw remarkable expansion, driven by increased market adoption of its Blood Volume Analysis (BVA^™) technology:

• Revenue Surge: Unaudited operating revenues increased by 45% year-over-year. This growth was fueled by sales of single-use diagnostic kits for heart failure and critical care, new account acquisitions, and revenue from military contracts.
• Operational Efficiency: The division realized an operating loss of $268,598, a significant improvement from the $1,614,545 loss in 2024. This move toward break-even performance comes despite heavy investment in R&D, sales team expansion, and production facilities for next-generation analyzers.
  
  

Strategic Capital & Corporate Transition

Subsequent to the 2025 year-end, Daxor successfully closed a $9 million registered direct offering in January 2026 at $11.75 per share. This capital injection, while not reflected in the 2025 year-end figures, significantly strengthens working capital for accelerated commercialization.

Additionally, the company has announced its intention to transition its regulatory reporting framework to the Securities Exchange Act of 1934. This move is expected to simplify financial disclosures and provide investors with standardized GAAP metrics comparable to other high-growth medical diagnostic firms.

“2025 marked a crucial inflection point for our company,” said Michael Feldschuh, Daxor CEO and President. “Our commitment to replacing clinical guesswork with precise measurement has culminated in a transformative year, reflected in our strong revenue growth and the strategic realignment of our corporate structure.”

About Daxor Corporation

Daxor Corporation (Nasdaq: DXR) is tackling healthcare's "multi-billion-dollar silent crisis", the inability to precisely measure blood volume. This often results in suboptimal care, prolonged hospital stays, and increased readmissions for many high-cost medical conditions like heart failure and those requiring ICU care. With 50 years of experience and innovation, Daxor is proud to manufacture and distribute its patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic which offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system. This empowers clinicians to make individualized treatment decisions that significantly improve patient outcomes and deliver substantial efficiencies in value-based healthcare. Daxor is ISO certified and operates a U.S.-based, 20,000-square-foot state-of-the-art manufacturing facility, positioning the company for accelerated market expansion.

Forward-Looking Statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact
Bret Shapiro
COO – Head of Capital Markets
COREIR
516-222-2560
brets@coreir.com|www.coreir.com

FAQ

What did Daxor (DXR) report for fiscal 2025 revenue and NAV per share?

Daxor reported unaudited operating revenue up 45% YoY and NAV per share of $9.07. According to the company, strong BVA kit sales and new accounts drove revenue growth and NAV rose by $1.82 per share year‑over‑year.

When did Daxor (DXR) receive FDA 510(k) clearance for its next‑generation analyzer?

Daxor received FDA 510(k) clearance in August 2025 for its portable Blood Volume Analyzer. According to the company, the cleared device delivers laboratory‑grade precision three times faster and supports accelerated commercial production and deployment.

How did Daxor's operating loss change in fiscal 2025 for DXR shareholders?

The operating loss narrowed to $268,598 in 2025 from $1,614,545 in 2024, an improvement. According to the company, this reflects higher revenues, R&D investment, and expanded sales effort moving the division toward break‑even.

What was the size and price of Daxor's January 2026 direct offering (DXR)?

Daxor closed a registered direct offering of $9.0 million in January 2026 at $11.75 per share. According to the company, proceeds strengthen working capital to support commercialization of next‑generation analyzers.

Why did Daxor (DXR) sell its remaining investment positions in December 2025?

Daxor sold remaining investments to focus resources entirely on its blood volume business. According to the company, this strategic shift concentrates capital and operations on BVA commercialization and product assembly for customer placements.

Will Daxor (DXR) change its regulatory reporting after fiscal 2025?

Daxor intends to transition its reporting framework to the Securities Exchange Act of 1934 for standardized disclosures. According to the company, the move aims to provide investors comparable GAAP metrics with other high‑growth medical diagnostic firms.